ReviewFrontiers in pharmacology2018
From Chemotherapy to Combined Targeted Therapeutics:
Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- ZC3H12D gene expression exhibits dual effects on the development and progression of lung adenocarcinoma.Scientific reports · 2025Article
- Application of biomechanics in tumor epigenetic research.Mechanobiology in medicine · 2024Review
- The use of organoids in creating immune microenvironments and treating gynecological tumors.Journal of translational medicine · 2024Review
- Exploring Tumor-Immune Interactions in Co-Culture Models of T Cells and Tumor Organoids Derived from Patients.International journal of molecular sciences · 2023Review
- Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.Genes & diseases · 2023Review
- Review
- Reproduction of the Antitumor Effect of Cisplatin and Cetuximab Using a Three-dimensional Spheroid Model in Oral Cancer.International journal of medical sciences · 2022Article
- 3D-culture models as drug-testing platforms in canine lymphoma and their cross talk with lymph node-derived stromal cells.Journal of veterinary science · 2021Article
- Precision Oncology Beyond Genomics: The Future Is Here-It Is Just Not Evenly Distributed.Cells · 2021Review
- Three-dimensional culture and clinical drug responses of a highly metastatic human ovarian cancer HO-8910PM cells in nanofibrous microenvironments of three hydrogel biomaterials.Journal of nanobiotechnology · 2020Article
- Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring UncommonFrontiers in oncology · 2020Article
- Enriching Personalized Endometrial Cancer Research with the Harmonization of Biobanking Standards.Cancers · 2019Review
- Utility of the JAX Clinical Knowledgebase in capture and assessment of complex genomic cancer data.NPJ precision oncology · 2019Article
- H1.0 Linker Histone as an Epigenetic Regulator of Cell Proliferation and Differentiation.Genes · 2018Review
- Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in next-generation sequencing and other omics technologies capable to map cell fate provide increasing evidence on the crucial role of intra-tumor heterogeneity (ITH) for cancer progression. The different facets of ITH, from genomic to microenvironmental heterogeneity and the hierarchical cellular architecture originating from the cancer stem cell compartment, contribute to the range of tumor phenotypes. Decoding these complex data resulting from the analysis of tumor tissue complexity poses a challenge for developing novel therapeutic strategies that can counteract tumor evolution and cellular plasticity. To achieve this aim, the development of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.